Angiology: Open Access

Angiology: Open Access
Open Access

ISSN: 2329-9495

+44 1478 350008

Satoru Shimizu

Satoru Shimizu

Department of Hygiene and Public Health, School of Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan,

Biography
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.

Relevant Topics

Top